ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$39.77
−0.53%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.41
- Revenue estimate
- $3.7M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.33
- EPS estimate
- -$0.30
- Revenue actual
- $1.4M
- Revenue estimate
- $2.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -5.2%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $50
- PT range
- $46 – $55
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.30 | -$0.33 | Miss -10.14% | $1.4M |
| May 20, 2026 | -$0.26 | -$0.36 | Miss -38.46% | $2.5M |
| Feb 6, 2026 | -$0.27 | -$0.24 | Beat 11.11% | $2.0M |
| May 29, 2025 | -$0.26 | -$0.22 | Beat 16.51% | $7.6M |
| Aug 8, 2024 | -$0.24 | -$0.18 | Beat 26.03% | $55.1M |
| May 30, 2024 | -$0.26 | -$0.23 | Beat 12.99% | $28.9M |
| Feb 13, 2024 | -$0.27 | -$0.21 | Beat 22.22% | $37.1M |
| Nov 13, 2023 | -$0.28 | -$0.26 | Beat 7.14% | $37.1M |
| Aug 14, 2023 | -$0.26 | -$0.38 | Miss -46.15% | $21.6M |
| Feb 13, 2023 | -$0.36 | -$0.49 | Miss -36.11% | $17.1M |
| Nov 14, 2022 | -$0.41 | -$0.42 | Miss -2.44% | $12.5M |
| Aug 15, 2022 | -$0.30 | -$0.48 | Miss -60.00% | $4.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026